Evaluation of the Efficacy Duration of Topical Therapies in Eyes with Primary Open-Angle Glaucoma

Lanza, Michele; Leone, Angelo; Scognamiglio, Gabriele; Serra, Luigi; Iodice, Clemente Maria; Melillo, Paolo; Simonelli, Francesca

doi:10.3390/jcm11206166

Cited by 2 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lanza, M et al (2022) 9 showed an accurate evaluation of the glaucomatous patient with POAG is crucial to selecting a proper IOP-lowering regime, in agreement with the most relevant international guidelines. A treatment selected with the awareness of the molecule interval of efficacy, indeed, would provide an adequate IOP reduction along with avoiding unexpected VF damage progressions and a concomitant reduction of quality of life.…”

Section: Patientsmentioning

confidence: 68%

Comparative of First Line Medications for Primary Open Angle Glaucoma : A Systematic Review

Rahmad

2023

JARMHS

View full text Add to dashboard Cite

Background: Glaucoma is the second leading cause of blindness globally, of which primary open-angle glaucoma (POAG) is the most common type, and its prevalence is estimated at 2 worldwide. The prevalence of glaucoma contributes to significant medical costs, and the majority of costs are medication related. Most medications used in the management of glaucoma are targeted at decreasing intraocular pressure (IOP), with each millimeter of mercury (mm Hg) IOP reduction shown to reduce the risk of glaucoma progression and subsequent vision loss by 10. The aim: This study aims to show the comparative of first line medications for primary open angle glaucoma. Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020, this study was able to show that it met all of the requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2013 and 2023 were taken into account. Several different online reference sources, like Pubmed and SagePub, were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done. Result: In the PubMed database, the results of our search on SagePub brought up 124 articles. The results of the search conducted for the last year of 2013 yielded a total 12 articles for PubMed and 34 articles for SagePub. The result from title screening, a total 10 articles for PubMed and 12 articles for SagePub. In the end, we compiled a total of 8 papers. We included five research that met the criteria. Conclusion: All active first-line drugs are among the most efficacious drugs, although the within class differences were small and may not be clinically meaningful. All factors, including adverse effects, patient preferences, and cost should be considered in selecting a drug for a given patient.

show abstract

Section: Patientsmentioning

confidence: 68%

Comparative of First Line Medications for Primary Open Angle Glaucoma : A Systematic Review

Rahmad

2023

JARMHS

View full text Add to dashboard Cite

show abstract

Topical hypotensive therapy preceding surgical treatment of glaucoma

Kuroyedov,

Gorodnichiy,

Gaponko

et al. 2023

Glaucoma

View full text Add to dashboard Cite

PURPOSE. To analyze specific clinical and epidemiological parameters of patients with primary open-angle glaucoma (POAG) who were admitted for surgical treatment to the ophthalmological hospital of a multi-specialty in-patient medical center in the period of 2021–2022 years.METHODS. The retrospective elective study analyzed data from 95 patients (95 eyes) with different stages of primary open-angle glaucoma (mean age 73 [67; 80] years old) who were hospitalized for surgical treatment of the disease in 2021–2022. In addition to standard ophthalmological examination, several clinical and epidemiologic characteristics were analyzed in detail, including the prevalence of prescriptions for antiglaucoma hypotensive drugs. Comparison of the obtained results with the data of similar procedures performed in the period from 2005 to 2016 was carried out.RESULTS. The number of main comorbid somatic diseases was on average 3 (2; 4), and comparison of conditions by disease stage revealed no significant differences (p>0.05). Mean duration of the disease (according to anamnesis) was 8 (4; 13) years and was longer in comparison with similar results from 2005–2006 presented in a previous study. The period preceding the first surgical intervention was 5 (2; 10) years and was statistically significantly longer in those with moderate stage of POAG (9 [3; 14] years) compared to those with early stage of POAG (4 [3; 5] years, p<0.05) and advanced stage of POAG (6 [0; 10] years, p<0.04). The average number of drugs at the time of hospitalization for surgical treatment has increased significantly in comparison with the data of the early-mid 2000s and amounted to 4 (3; 4) units (stage I glaucoma — 3 [3; 4]; stage II — 4 [3; 4]; stage III — 4 [3; 4] units), with no statistically significant difference (p1,2=0.64; p1,3=0.21; p2,3=0.42, respectively).CONCLUSION. Unwarranted long-term use of a large number of antiglaucoma drugs ("maximal medication therapy adherence") is a significant problem in modern glaucomatology and can evidently affect future prognosis of the disease.

show abstract

Evaluation of the Efficacy Duration of Topical Therapies in Eyes with Primary Open-Angle Glaucoma

Cited by 2 publications

References 29 publications

Comparative of First Line Medications for Primary Open Angle Glaucoma : A Systematic Review

Comparative of First Line Medications for Primary Open Angle Glaucoma : A Systematic Review

Topical hypotensive therapy preceding surgical treatment of glaucoma

Contact Info

Product

Resources

About